Current Report Filing (8-k)
November 14 2017 - 4:05PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 14, 2017
OCEAN
BIO-CHEM, INC.
(Exact
name of registrant as specified in charter)
Florida
|
|
0-11102
|
|
59-1564329
|
(State
or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification No.)
|
4041
S.W. 47 Avenue, Fort Lauderdale, Florida
|
|
33314
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
(954)
587-6280
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item
2.02. Results of Operations and Financial Condition
On
November 14, 2017, Ocean Bio-Chem, Inc. (the “Company”) issued a press release announcing its financial results for
the third quarter ended September 30, 2017. A copy of the press release is furnished as Exhibit 99.1 to this Current Report.
The
information furnished pursuant to Item 2.02 of this Current Report, including the exhibit furnished herewith, shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that section, nor shall it be incorporated by reference into future filings by the Company under the Securities
Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in
such future filing that such information is to be considered “filed” or incorporated by reference therein.
Item 9.01
Financial Statements and Exhibits
(d) Exhibits
The
Company is furnishing the following exhibit to this Current Report:
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
OCEAN
BIO-CHEM, INC.
|
|
|
|
Date:
November 14, 2017
|
By:
|
/s/
Jeffrey S. Barocas
|
|
|
Jeffrey
S. Barocas
|
|
|
Chief
Financial Officer
|
3
Ocean Bio Chem (NASDAQ:OBCI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocean Bio Chem (NASDAQ:OBCI)
Historical Stock Chart
From Apr 2023 to Apr 2024